Latest Pharma Insights
Geneoscopy RNA-Based Colorectal Cancer Test Now Available Nationwide Through Labcorp
Labcorp has announced the availability of the ColoSense colorectal screening test across the US. The announcement marks the first FDA-approved at-home test that uses RNA technology to detect biomarkers associated with both colorectal cancer and precancerous changes that may point to disease.
Medtech Insight - June 26, 2026
Labcorp has announced the availability of the ColoSense colorectal screening test across the US. The announcement marks the first FDA-approved at-home test that uses RNA technology to detect biomarkers associated with both colorectal cancer and precancerous changes that may point to disease.
Medtech Insight - June 26, 2026
Callio Makes The Case For Dual-Payload ADCs
Callio has been among the vanguard of drug developers focusing on dual-payload antibody-drug conjugates and has its first program in a Phase I trial. CSO Jerome Boyd-Kirkup explained the progress and promise of dual-payload ADCs in an interview at ASCO.
Scrip - June 26, 2026
Callio has been among the vanguard of drug developers focusing on dual-payload antibody-drug conjugates and has its first program in a Phase I trial. CSO Jerome Boyd-Kirkup explained the progress and promise of dual-payload ADCs in an interview at ASCO.
Scrip - June 26, 2026
Siemens Healthineers Awarded $6.9M Contract With ARPA-H Cybersecurity Initiative
Siemens Healthineers secured a $6.9m contract from ARPA-H to develop an AI-powered cybersecurity patching systems for two hospitals, addressing the growing vulnerability of health systems that are faced with unique challenges to thwart against cyber threats.
Medtech Insight - June 26, 2026
Siemens Healthineers secured a $6.9m contract from ARPA-H to develop an AI-powered cybersecurity patching systems for two hospitals, addressing the growing vulnerability of health systems that are faced with unique challenges to thwart against cyber threats.
Medtech Insight - June 26, 2026
Signos Study: Engagement With AI Metabolic App Nearly Triples Weekly Weight Loss Rate
Adults with obesity who actively used a CGM-integrated AI coaching platform lost weight nearly three times faster than during disengaged periods, a 3,007-participant retrospective study shows — with consistent results across obesity classes, sexes, and age groups regardless of when engagement began.
Medtech Insight - June 26, 2026
Adults with obesity who actively used a CGM-integrated AI coaching platform lost weight nearly three times faster than during disengaged periods, a 3,007-participant retrospective study shows — with consistent results across obesity classes, sexes, and age groups regardless of when engagement began.
Medtech Insight - June 26, 2026
Pfizer Discontinues Vizimpro In US Amid Oncologist Preference Shift
Pfizer has discontinued Vizimpro (dacomitinib) in the US even as other drugs like Tagrisso moved to preferred status in NCCN’s guideline issued in November last year. While Pfizer does not break out sales for Vizimpro, Tagrisso grew to become AstaZeneca’s largest brand in 2025
Scrip - June 26, 2026
Pfizer has discontinued Vizimpro (dacomitinib) in the US even as other drugs like Tagrisso moved to preferred status in NCCN’s guideline issued in November last year. While Pfizer does not break out sales for Vizimpro, Tagrisso grew to become AstaZeneca’s largest brand in 2025
Scrip - June 26, 2026
Encouraging Signs For Revolution’s Pancreatic Cancer Combinations
The company is moving to expand its presence in pancreatic cancer by combining its Phase III monotherapy hit daraxonrasib with its G12D-targeting candidate, zoldonrasib
Scrip - June 26, 2026
The company is moving to expand its presence in pancreatic cancer by combining its Phase III monotherapy hit daraxonrasib with its G12D-targeting candidate, zoldonrasib
Scrip - June 26, 2026
AI May Revitalize In-Store Beauty Experience – Tech Firm
Emerging AI technologies are giving beauty retailers new ways to make brick-and-mortar shopping more valuable in an increasingly digital marketplace.
HBW Insight - June 26, 2026
Emerging AI technologies are giving beauty retailers new ways to make brick-and-mortar shopping more valuable in an increasingly digital marketplace.
HBW Insight - June 26, 2026
US Approves First Rifapentine Generic
The US FDA has approved the first generic version of rifapentine (Priftin) 28–years after Sanofi’s approval, expanding patient access to TB treatment.
Generics Bulletin - June 26, 2026
The US FDA has approved the first generic version of rifapentine (Priftin) 28–years after Sanofi’s approval, expanding patient access to TB treatment.
Generics Bulletin - June 26, 2026
Stada Acquires Orifarm VMS Brands To Emerge As Major Nordic CHC Player
Stada tells HBW Insight that its acquisition of Orifarm's dietary supplements portfolio will make the company one of the Nordics' top consumer health players.
HBW Insight - June 26, 2026
Stada tells HBW Insight that its acquisition of Orifarm's dietary supplements portfolio will make the company one of the Nordics' top consumer health players.
HBW Insight - June 26, 2026
Pivotal Phase II Results Advance HUTCHMED’s Fanregratinib Towards China Approval In ICC
Fanregratinib's latest data readout marks an important regulatory milestone for HUTCHMED as it seeks to broaden its portfolio of targeted oncology therapies in China.
Scrip - June 26, 2026
Fanregratinib's latest data readout marks an important regulatory milestone for HUTCHMED as it seeks to broaden its portfolio of targeted oncology therapies in China.
Scrip - June 26, 2026
Merck KGaA Doubles Down On Life Sciences With $11.3bn Bio-Techne Buyout
Merck KGaA will buy US lab-tools maker Bio-Techne for $11.3bn, its biggest deal since 2015, to expand in cell and gene therapy and precision diagnostics.
Scrip - June 26, 2026
Merck KGaA will buy US lab-tools maker Bio-Techne for $11.3bn, its biggest deal since 2015, to expand in cell and gene therapy and precision diagnostics.
Scrip - June 26, 2026
Big Pharma Boards Move AI From Strategy Slide To Paycheck
New analysis of proxy statements from ten of the world's largest pharmaceutical companies finds that 2025 was first year in which AI featured in NEO compensation reports at a majority of firms.
Scrip - June 26, 2026
New analysis of proxy statements from ten of the world's largest pharmaceutical companies finds that 2025 was first year in which AI featured in NEO compensation reports at a majority of firms.
Scrip - June 26, 2026
Ionis Inks Zilganersen Pact With Recordati To Zero In On US
Deal Snapshot: Its licensing agreement with the Italian firm for the Alexander disease drug sees Ionis follow the business development approach of biotech trailblazers Genentech and Regeneron by firmly focusing on the US market.
Scrip - June 26, 2026
Deal Snapshot: Its licensing agreement with the Italian firm for the Alexander disease drug sees Ionis follow the business development approach of biotech trailblazers Genentech and Regeneron by firmly focusing on the US market.
Scrip - June 26, 2026
Regulatory Recap: US Senate Committee Passes Two Off-Patent Bills But Delays Generics Access Act
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - June 26, 2026
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - June 26, 2026
Tanvex Hits Strike Three On US Trastuzumab Biosimilar
Tanvex’s US trastuzumab biosimilar TX05 has drawn a third FDA complete response letter, with the latest setback again tied to its third-party downstream manufacturer rather than the biosimilar’s drug substance.
Generics Bulletin - June 26, 2026
Tanvex’s US trastuzumab biosimilar TX05 has drawn a third FDA complete response letter, with the latest setback again tied to its third-party downstream manufacturer rather than the biosimilar’s drug substance.
Generics Bulletin - June 26, 2026
TISSIUM’s Sutureless Surgery Bet Clears FDA But Needs To Win With Surgeons
Backed by €60m and an FDA authorization, TISSIUM is rolling out a sutureless repair system for peripheral nerve repair – and testing whether surgeons will trade thread for light.
Medtech Insight - June 26, 2026
Backed by €60m and an FDA authorization, TISSIUM is rolling out a sutureless repair system for peripheral nerve repair – and testing whether surgeons will trade thread for light.
Medtech Insight - June 26, 2026
Recertifications And AI High On EU Parliament’s MDR/IVDR Negotiation Priorities
EU co-legislator negotiations on the European Commission’s targeted amendments to the MDR and IVDR reached their first major stage this week when the European Parliament’s IMCO committee presented its draft opinion.
Medtech Insight - June 26, 2026
EU co-legislator negotiations on the European Commission’s targeted amendments to the MDR and IVDR reached their first major stage this week when the European Parliament’s IMCO committee presented its draft opinion.
Medtech Insight - June 26, 2026
Korean Pilot Project Lets Hospitals Securely Share Data For AI Training
Consortium of 48 organizations, including hospitals and tech firms, will collaborate on federated space for sharing medical records without exporting data.
Medtech Insight - June 26, 2026
Consortium of 48 organizations, including hospitals and tech firms, will collaborate on federated space for sharing medical records without exporting data.
Medtech Insight - June 26, 2026
UK Working With US And EU On New Validation Center For Animal Testing Alternatives
UK’s forthcoming Centre for the Validation of Alternative Methods being designed with international coordination in mind, as part of government’s strategy to phase out animal testing, senior official says.
HBW Insight - June 26, 2026
UK’s forthcoming Centre for the Validation of Alternative Methods being designed with international coordination in mind, as part of government’s strategy to phase out animal testing, senior official says.
HBW Insight - June 26, 2026
HistoSonics Lifts Valuation To $3.75bn, Eyes Kidney De Novo Decision
With backing from Reed Jobs and Yosemite, HistoSonics’ $3.75bn valuation comes as the company pursues kidney and pancreatic tumor indications alongside expanding liver-tumor adoption.
Medtech Insight - June 26, 2026
With backing from Reed Jobs and Yosemite, HistoSonics’ $3.75bn valuation comes as the company pursues kidney and pancreatic tumor indications alongside expanding liver-tumor adoption.
Medtech Insight - June 26, 2026
Korean Pharma Joins Global AI Boom Amid State Support
Korean pharma companies are rapidly integrating AI across drug discovery, manufacturing and patient management, driven by both corporate strategy and aggressive government-backed AI investment programs.
Scrip - June 26, 2026
Korean pharma companies are rapidly integrating AI across drug discovery, manufacturing and patient management, driven by both corporate strategy and aggressive government-backed AI investment programs.
Scrip - June 26, 2026
New Takeda CEO Targets Return To ‘Modest Growth’ Within Three Years
Takeda's new CEO emphasizes upcoming launches and late-stage assets as she takes charge, while conceding the Japanese firm's earlier pipeline might need some help.
Scrip - June 26, 2026
Takeda's new CEO emphasizes upcoming launches and late-stage assets as she takes charge, while conceding the Japanese firm's earlier pipeline might need some help.
Scrip - June 26, 2026
Automating Clinical Decisions For Healthcare System Efficiencies
AI-enabled workflow-centric approaches are gaining currency as health systems and life science innovators see potential to slash administrative bloat, accelerate clinical trials and optimize clinical operations. But there remains a chasm between AI healthcare promises and clinical reality.
In Vivo - June 26, 2026
AI-enabled workflow-centric approaches are gaining currency as health systems and life science innovators see potential to slash administrative bloat, accelerate clinical trials and optimize clinical operations. But there remains a chasm between AI healthcare promises and clinical reality.
In Vivo - June 26, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry, marketplace news: Trump urges helping hemp industry; DEA marijuana scheduling hearing set; TEA OTC pathway end planned; FDA’s “Real Cost” tobacco prevention campaigns results; OMUFA arrears list grows; more.
HBW Insight - June 26, 2026
Weekly digest of US consumer health industry, marketplace news: Trump urges helping hemp industry; DEA marijuana scheduling hearing set; TEA OTC pathway end planned; FDA’s “Real Cost” tobacco prevention campaigns results; OMUFA arrears list grows; more.
HBW Insight - June 26, 2026
Callio Makes The Case For Dual-Payload ADCs
Callio has been among the vanguard of drug developers focusing on dual-payload antibody-drug conjugates and has its first program in a Phase I trial. CSO Jerome Boyd-Kirkup explained the progress and promise of dual-payload ADCs in an interview at ASCO.
Scrip - June 26, 2026
Callio has been among the vanguard of drug developers focusing on dual-payload antibody-drug conjugates and has its first program in a Phase I trial. CSO Jerome Boyd-Kirkup explained the progress and promise of dual-payload ADCs in an interview at ASCO.
Scrip - June 26, 2026
Pfizer Discontinues Vizimpro In US Amid Oncologist Preference Shift
Pfizer has discontinued Vizimpro (dacomitinib) in the US even as other drugs like Tagrisso moved to preferred status in NCCN’s guideline issued in November last year. While Pfizer does not break out sales for Vizimpro, Tagrisso grew to become AstaZeneca’s largest brand in 2025
Scrip - June 26, 2026
Pfizer has discontinued Vizimpro (dacomitinib) in the US even as other drugs like Tagrisso moved to preferred status in NCCN’s guideline issued in November last year. While Pfizer does not break out sales for Vizimpro, Tagrisso grew to become AstaZeneca’s largest brand in 2025
Scrip - June 26, 2026
Encouraging Signs For Revolution’s Pancreatic Cancer Combinations
The company is moving to expand its presence in pancreatic cancer by combining its Phase III monotherapy hit daraxonrasib with its G12D-targeting candidate, zoldonrasib
Scrip - June 26, 2026
The company is moving to expand its presence in pancreatic cancer by combining its Phase III monotherapy hit daraxonrasib with its G12D-targeting candidate, zoldonrasib
Scrip - June 26, 2026
Pivotal Phase II Results Advance HUTCHMED’s Fanregratinib Towards China Approval In ICC
Fanregratinib's latest data readout marks an important regulatory milestone for HUTCHMED as it seeks to broaden its portfolio of targeted oncology therapies in China.
Scrip - June 26, 2026
Fanregratinib's latest data readout marks an important regulatory milestone for HUTCHMED as it seeks to broaden its portfolio of targeted oncology therapies in China.
Scrip - June 26, 2026
Merck KGaA Doubles Down On Life Sciences With $11.3bn Bio-Techne Buyout
Merck KGaA will buy US lab-tools maker Bio-Techne for $11.3bn, its biggest deal since 2015, to expand in cell and gene therapy and precision diagnostics.
Scrip - June 26, 2026
Merck KGaA will buy US lab-tools maker Bio-Techne for $11.3bn, its biggest deal since 2015, to expand in cell and gene therapy and precision diagnostics.
Scrip - June 26, 2026
Big Pharma Boards Move AI From Strategy Slide To Paycheck
New analysis of proxy statements from ten of the world's largest pharmaceutical companies finds that 2025 was first year in which AI featured in NEO compensation reports at a majority of firms.
Scrip - June 26, 2026
New analysis of proxy statements from ten of the world's largest pharmaceutical companies finds that 2025 was first year in which AI featured in NEO compensation reports at a majority of firms.
Scrip - June 26, 2026
Ionis Inks Zilganersen Pact With Recordati To Zero In On US
Deal Snapshot: Its licensing agreement with the Italian firm for the Alexander disease drug sees Ionis follow the business development approach of biotech trailblazers Genentech and Regeneron by firmly focusing on the US market.
Scrip - June 26, 2026
Deal Snapshot: Its licensing agreement with the Italian firm for the Alexander disease drug sees Ionis follow the business development approach of biotech trailblazers Genentech and Regeneron by firmly focusing on the US market.
Scrip - June 26, 2026
Korean Pharma Joins Global AI Boom Amid State Support
Korean pharma companies are rapidly integrating AI across drug discovery, manufacturing and patient management, driven by both corporate strategy and aggressive government-backed AI investment programs.
Scrip - June 26, 2026
Korean pharma companies are rapidly integrating AI across drug discovery, manufacturing and patient management, driven by both corporate strategy and aggressive government-backed AI investment programs.
Scrip - June 26, 2026
New Takeda CEO Targets Return To ‘Modest Growth’ Within Three Years
Takeda's new CEO emphasizes upcoming launches and late-stage assets as she takes charge, while conceding the Japanese firm's earlier pipeline might need some help.
Scrip - June 26, 2026
Takeda's new CEO emphasizes upcoming launches and late-stage assets as she takes charge, while conceding the Japanese firm's earlier pipeline might need some help.
Scrip - June 26, 2026
Geneoscopy RNA-Based Colorectal Cancer Test Now Available Nationwide Through Labcorp
Labcorp has announced the availability of the ColoSense colorectal screening test across the US. The announcement marks the first FDA-approved at-home test that uses RNA technology to detect biomarkers associated with both colorectal cancer and precancerous changes that may point to disease.
Medtech Insight - June 26, 2026
Labcorp has announced the availability of the ColoSense colorectal screening test across the US. The announcement marks the first FDA-approved at-home test that uses RNA technology to detect biomarkers associated with both colorectal cancer and precancerous changes that may point to disease.
Medtech Insight - June 26, 2026
Siemens Healthineers Awarded $6.9M Contract With ARPA-H Cybersecurity Initiative
Siemens Healthineers secured a $6.9m contract from ARPA-H to develop an AI-powered cybersecurity patching systems for two hospitals, addressing the growing vulnerability of health systems that are faced with unique challenges to thwart against cyber threats.
Medtech Insight - June 26, 2026
Siemens Healthineers secured a $6.9m contract from ARPA-H to develop an AI-powered cybersecurity patching systems for two hospitals, addressing the growing vulnerability of health systems that are faced with unique challenges to thwart against cyber threats.
Medtech Insight - June 26, 2026
Signos Study: Engagement With AI Metabolic App Nearly Triples Weekly Weight Loss Rate
Adults with obesity who actively used a CGM-integrated AI coaching platform lost weight nearly three times faster than during disengaged periods, a 3,007-participant retrospective study shows — with consistent results across obesity classes, sexes, and age groups regardless of when engagement began.
Medtech Insight - June 26, 2026
Adults with obesity who actively used a CGM-integrated AI coaching platform lost weight nearly three times faster than during disengaged periods, a 3,007-participant retrospective study shows — with consistent results across obesity classes, sexes, and age groups regardless of when engagement began.
Medtech Insight - June 26, 2026
TISSIUM’s Sutureless Surgery Bet Clears FDA But Needs To Win With Surgeons
Backed by €60m and an FDA authorization, TISSIUM is rolling out a sutureless repair system for peripheral nerve repair – and testing whether surgeons will trade thread for light.
Medtech Insight - June 26, 2026
Backed by €60m and an FDA authorization, TISSIUM is rolling out a sutureless repair system for peripheral nerve repair – and testing whether surgeons will trade thread for light.
Medtech Insight - June 26, 2026
Recertifications And AI High On EU Parliament’s MDR/IVDR Negotiation Priorities
EU co-legislator negotiations on the European Commission’s targeted amendments to the MDR and IVDR reached their first major stage this week when the European Parliament’s IMCO committee presented its draft opinion.
Medtech Insight - June 26, 2026
EU co-legislator negotiations on the European Commission’s targeted amendments to the MDR and IVDR reached their first major stage this week when the European Parliament’s IMCO committee presented its draft opinion.
Medtech Insight - June 26, 2026
Korean Pilot Project Lets Hospitals Securely Share Data For AI Training
Consortium of 48 organizations, including hospitals and tech firms, will collaborate on federated space for sharing medical records without exporting data.
Medtech Insight - June 26, 2026
Consortium of 48 organizations, including hospitals and tech firms, will collaborate on federated space for sharing medical records without exporting data.
Medtech Insight - June 26, 2026
HistoSonics Lifts Valuation To $3.75bn, Eyes Kidney De Novo Decision
With backing from Reed Jobs and Yosemite, HistoSonics’ $3.75bn valuation comes as the company pursues kidney and pancreatic tumor indications alongside expanding liver-tumor adoption.
Medtech Insight - June 26, 2026
With backing from Reed Jobs and Yosemite, HistoSonics’ $3.75bn valuation comes as the company pursues kidney and pancreatic tumor indications alongside expanding liver-tumor adoption.
Medtech Insight - June 26, 2026
AI May Revitalize In-Store Beauty Experience – Tech Firm
Emerging AI technologies are giving beauty retailers new ways to make brick-and-mortar shopping more valuable in an increasingly digital marketplace.
HBW Insight - June 26, 2026
Emerging AI technologies are giving beauty retailers new ways to make brick-and-mortar shopping more valuable in an increasingly digital marketplace.
HBW Insight - June 26, 2026
Stada Acquires Orifarm VMS Brands To Emerge As Major Nordic CHC Player
Stada tells HBW Insight that its acquisition of Orifarm's dietary supplements portfolio will make the company one of the Nordics' top consumer health players.
HBW Insight - June 26, 2026
Stada tells HBW Insight that its acquisition of Orifarm's dietary supplements portfolio will make the company one of the Nordics' top consumer health players.
HBW Insight - June 26, 2026
UK Working With US And EU On New Validation Center For Animal Testing Alternatives
UK’s forthcoming Centre for the Validation of Alternative Methods being designed with international coordination in mind, as part of government’s strategy to phase out animal testing, senior official says.
HBW Insight - June 26, 2026
UK’s forthcoming Centre for the Validation of Alternative Methods being designed with international coordination in mind, as part of government’s strategy to phase out animal testing, senior official says.
HBW Insight - June 26, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry, marketplace news: Trump urges helping hemp industry; DEA marijuana scheduling hearing set; TEA OTC pathway end planned; FDA’s “Real Cost” tobacco prevention campaigns results; OMUFA arrears list grows; more.
HBW Insight - June 26, 2026
Weekly digest of US consumer health industry, marketplace news: Trump urges helping hemp industry; DEA marijuana scheduling hearing set; TEA OTC pathway end planned; FDA’s “Real Cost” tobacco prevention campaigns results; OMUFA arrears list grows; more.
HBW Insight - June 26, 2026
US Approves First Rifapentine Generic
The US FDA has approved the first generic version of rifapentine (Priftin) 28–years after Sanofi’s approval, expanding patient access to TB treatment.
Generics Bulletin - June 26, 2026
The US FDA has approved the first generic version of rifapentine (Priftin) 28–years after Sanofi’s approval, expanding patient access to TB treatment.
Generics Bulletin - June 26, 2026
Regulatory Recap: US Senate Committee Passes Two Off-Patent Bills But Delays Generics Access Act
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - June 26, 2026
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - June 26, 2026
Tanvex Hits Strike Three On US Trastuzumab Biosimilar
Tanvex’s US trastuzumab biosimilar TX05 has drawn a third FDA complete response letter, with the latest setback again tied to its third-party downstream manufacturer rather than the biosimilar’s drug substance.
Generics Bulletin - June 26, 2026
Tanvex’s US trastuzumab biosimilar TX05 has drawn a third FDA complete response letter, with the latest setback again tied to its third-party downstream manufacturer rather than the biosimilar’s drug substance.
Generics Bulletin - June 26, 2026
Automating Clinical Decisions For Healthcare System Efficiencies
AI-enabled workflow-centric approaches are gaining currency as health systems and life science innovators see potential to slash administrative bloat, accelerate clinical trials and optimize clinical operations. But there remains a chasm between AI healthcare promises and clinical reality.
In Vivo - June 26, 2026
AI-enabled workflow-centric approaches are gaining currency as health systems and life science innovators see potential to slash administrative bloat, accelerate clinical trials and optimize clinical operations. But there remains a chasm between AI healthcare promises and clinical reality.
In Vivo - June 26, 2026